Objective:To assess the prevalence of malaria parasitemia in north-east Nigeria and to evaluate the measures for the prevention of malaria.Methods:A village in north-eastern Nigeria was selected for the cross sectiona...Objective:To assess the prevalence of malaria parasitemia in north-east Nigeria and to evaluate the measures for the prevention of malaria.Methods:A village in north-eastern Nigeria was selected for the cross sectional study at the height of the rainy season in October 2011.A total of 550 inhabitants of a hamlet were recruited for this study.After obtaining the consent individuals received a structured interview and were tested for malaria parasites in their blood films.Recruits testing positive for malaria were given a course of artemesinin-based combination therapy（ACT）.Results:A total of 497 inhabitants representing approximately 90 percent of the population participated:a quarter of the study group carried malaria parasitesexclusively Plasmodium falciparum（P.falciparum）-representing a P.falciparum parasite rate（PfPR） of 24.5%.Besides,53/138 in the age group of 2 to 【 10 years old children tested positive for P.falciparum representing a PfPR2-10 value of 38.4%.Malaria control measures were used in just under a third（157/497） of this cohort.Despite these measures 28/157（17.8%） still tested positive for P.falciparum.Conclusions:The malaria burden is overestimated for this region in north-east Nigeria.The findings support an intermediate pattern of malaria endemicity.The 30%bed nets coverage for malaria control is well below the WHO estimates for 2011.展开更多
Objective:To investigate resistance and safety of HHPG-19K in treating non-small cell lung cancer patients.Methods:A total of 30 cases were selected and randomly divided into 5 groups:three HHPG-19K groups of differen...Objective:To investigate resistance and safety of HHPG-19K in treating non-small cell lung cancer patients.Methods:A total of 30 cases were selected and randomly divided into 5 groups:three HHPG-19K groups of different dosage(60 μg/kg/day,100 μ g/kg/day,200 μ g/ kg/day),positive control group(Filgrastim,namely G-CSF5 μ g/kg/day) and negative control group.Safety indexes of 5 groups were observed and compared.Results:All patients had adverse event(100%) in three HHPG-19K groups,and increased ALP,ALT and AST were main events.The degree was mild to moderate.There was no significant difference in the incidence of adverse event between dosage groups and positive control group no difference.But the incidence of negative control group was 13%,which was significantly lower than dosage groups and positive control group.Conclusions:Non-small cell lung cancer patients have satisfactory tolerance to HHPG-19K,and have no resistance.Besides,dosage at 100 μ g/kg is the most safe.展开更多
文摘Objective:To assess the prevalence of malaria parasitemia in north-east Nigeria and to evaluate the measures for the prevention of malaria.Methods:A village in north-eastern Nigeria was selected for the cross sectional study at the height of the rainy season in October 2011.A total of 550 inhabitants of a hamlet were recruited for this study.After obtaining the consent individuals received a structured interview and were tested for malaria parasites in their blood films.Recruits testing positive for malaria were given a course of artemesinin-based combination therapy（ACT）.Results:A total of 497 inhabitants representing approximately 90 percent of the population participated:a quarter of the study group carried malaria parasitesexclusively Plasmodium falciparum（P.falciparum）-representing a P.falciparum parasite rate（PfPR） of 24.5%.Besides,53/138 in the age group of 2 to 【 10 years old children tested positive for P.falciparum representing a PfPR2-10 value of 38.4%.Malaria control measures were used in just under a third（157/497） of this cohort.Despite these measures 28/157（17.8%） still tested positive for P.falciparum.Conclusions:The malaria burden is overestimated for this region in north-east Nigeria.The findings support an intermediate pattern of malaria endemicity.The 30%bed nets coverage for malaria control is well below the WHO estimates for 2011.
文摘Objective:To investigate resistance and safety of HHPG-19K in treating non-small cell lung cancer patients.Methods:A total of 30 cases were selected and randomly divided into 5 groups:three HHPG-19K groups of different dosage(60 μg/kg/day,100 μ g/kg/day,200 μ g/ kg/day),positive control group(Filgrastim,namely G-CSF5 μ g/kg/day) and negative control group.Safety indexes of 5 groups were observed and compared.Results:All patients had adverse event(100%) in three HHPG-19K groups,and increased ALP,ALT and AST were main events.The degree was mild to moderate.There was no significant difference in the incidence of adverse event between dosage groups and positive control group no difference.But the incidence of negative control group was 13%,which was significantly lower than dosage groups and positive control group.Conclusions:Non-small cell lung cancer patients have satisfactory tolerance to HHPG-19K,and have no resistance.Besides,dosage at 100 μ g/kg is the most safe.
